These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 34610837)

  • 1. Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
    Katayama T; Sawada J; Takahashi K; Yahara O; Hasebe N
    Alzheimers Res Ther; 2021 Oct; 13(1):163. PubMed ID: 34610837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
    Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
    J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease.
    Joki H; Higashiyama Y; Nakae Y; Kugimoto C; Doi H; Kimura K; Kishida H; Ueda N; Nakano T; Takahashi T; Koyano S; Takeuchi H; Tanaka F
    J Neurol Sci; 2018 Feb; 385():99-104. PubMed ID: 29406924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex ratio in dementia with Lewy bodies balanced between Alzheimer's disease and Parkinson's disease dementia: a cross-sectional study.
    Mouton A; Blanc F; Gros A; Manera V; Fabre R; Sauleau E; Gomez-Luporsi I; Tifratene K; Friedman L; Thümmler S; Pradier C; Robert PH; David R
    Alzheimers Res Ther; 2018 Sep; 10(1):92. PubMed ID: 30208961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia.
    Gmitterová K; Gawinecka J; Llorens F; Varges D; Valkovič P; Zerr I
    Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):461-470. PubMed ID: 30083957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurodegeneration and Glial Activation Related CSF Biomarker as the Diagnosis of Alzheimer's Disease: A Systematic Review and an Updated Meta- analysis.
    Hao Y; Liu X; Zhu R
    Curr Alzheimer Res; 2022; 19(1):32-46. PubMed ID: 34879804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
    Jellinger KA
    J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, distribution, and severity of cerebral amyloid angiopathy differ between Lewy body diseases and Alzheimer's disease.
    Walker L; Simpson H; Thomas AJ; Attems J
    Acta Neuropathol Commun; 2024 Feb; 12(1):28. PubMed ID: 38360761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders.
    Wang ZY; Han ZM; Liu QF; Tang W; Ye K; Yao YY
    Int Psychogeriatr; 2015 Sep; 27(9):1429-38. PubMed ID: 25851548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies.
    Tam CW; Burton EJ; McKeith IG; Burn DJ; O'Brien JT
    Neurology; 2005 Mar; 64(5):861-5. PubMed ID: 15753423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease.
    Tateno F; Sakakibara R; Kawai T; Kishi M; Murano T
    Alzheimer Dis Assoc Disord; 2012; 26(3):213-6. PubMed ID: 22037599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy.
    Shimada H; Shinotoh H; Hirano S; Miyoshi M; Sato K; Tanaka N; Ota T; Fukushi K; Irie T; Ito H; Higuchi M; Kuwabara S; Suhara T
    Mov Disord; 2013 Feb; 28(2):169-75. PubMed ID: 23225334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of pathological markers in Parkinson's disease dementia post-mortem brains compared to dementia with Lewy bodies.
    Tu H; Zhang ZW; Qiu L; Lin Y; Jiang M; Chia SY; Wei Y; Ng ASL; Reynolds R; Tan EK; Zeng L
    BMC Neurosci; 2022 Jan; 23(1):3. PubMed ID: 34983390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease.
    Mito Y; Yoshida K; Yabe I; Makino K; Hirotani M; Tashiro K; Kikuchi S; Sasaki H
    Clin Neurol Neurosurg; 2005 Aug; 107(5):396-403. PubMed ID: 16023534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease.
    van der Zee S; Vermeiren Y; Fransen E; Van Dam D; Aerts T; Gerritsen MJ; Spikman JM; van Laar T; De Deyn PP
    J Parkinsons Dis; 2018; 8(1):71-84. PubMed ID: 29480224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.